Fama Bona klinika - Company finances
|
EUR
|
2018
From: 2018-01-01
To: 2018-12-31
|
2019
From: 2019-01-01
To: 2019-12-31
|
2020
From: 2020-01-01
To: 2020-12-31
|
2021
From: 2021-01-01
To: 2021-12-31
|
2022
From: 2022-01-01
To: 2022-12-31
|
2023
From: 2023-01-01
To: 2023-12-31
|
2024
From: 2024-01-01
To: 2024-12-31
|
2025
From: 2025-01-01
To: 2025-12-31
|
|---|---|---|---|---|---|---|---|---|
|
Financial data
|
||||||||
| Sales revenue | 20,774 | 28,678 | 35,376 | 44,925 | 55,743 | 72,660 | 71,200 | 76,632 |
| Profit before tax | -15,624 | -7,541 | 6,644 | 6,203 | 9,763 | 27,357 | 17,969 | 11,933 |
| Net profit | -15,624 | -7,541 | 6,342 | 6,051 | 9,446 | 27,017 | 17,415 | 11,360 |
| Equity | -67,489 | -75,030 | -68,688 | -62,637 | -53,191 | -26,174 | -8,759 | 2,601 |
| Liabilities | 77,351 | 85,652 | 93,629 | 101,536 | 116,131 | 122,751 | 137,973 | 141,372 |
| Non-current assets | 6,063 | 5,009 | 3,955 | 5,369 | 3,889 | 3,220 | 1,735 | 1,265 |
| Current assets | 3,799 | 5,613 | 20,986 | 33,530 | 59,051 | 93,357 | 127,479 | 142,708 |
| Total assets | 9,862 | 10,622 | 24,941 | 38,899 | 62,940 | 96,577 | 129,214 | 143,973 |
|
Taxes paid
|
||||||||
| STI taxes | - | - | - | - | - | 5,724 | 6,656 | 8,846 |
| Social insurance contributions | - | - | - | - | - | 7,052 | 8,390 | 12,167 |
|
Financial indicators
|
||||||||
| Revenue change y/y | +14.1% | +38.0% | +23.4% | +27.0% | +24.1% | +30.3% | -2.0% | +7.6% |
| ROA Return on Assets (ROA). The ratio of net profit to assets. Indicates the company's efficiency. | -158.4% | -71.0% | 25.4% | 15.6% | 15.0% | 28.0% | 13.5% | 7.9% |
| ROE Return on equity. The ratio of net profit to equity. Shows the return to shareholders. | - | - | - | - | - | - | - | 436.8% |
| Profit margin Net profit margin. Shows the overall profitability of the company. | -75.2% | -26.3% | 17.9% | 13.5% | 16.9% | 37.2% | 24.5% | 14.8% |
| EBT% EBT (Earnings Before Taxes) to revenue ratio. Shows the overall profitability of the company. | -75.2% | -26.3% | 18.8% | 13.8% | 17.5% | 37.7% | 25.2% | 15.6% |
| Liabilities/Equity The debt-to-equity ratio shows the company's capital structure. | - | - | - | - | - | - | - | 54.4 |
| Revenue per employee Ratio of revenue to the average annual number of employees. Indicates company efficiency. | 1,484 | 2,048 | 2,604 | 2,962 | 3,216 | 3,775 | 3,884 | 4,016 |
Sales revenue
See Scoris data in Google Search
Mark Scoris as a favorite source. One click, no registration.
Fama Bona klinika - Social security debts
| From | To | Debt, € |
|---|---|---|
| 2026-03-27 | 2026-03-27 | 999.24 |
| 2026-03-17 | 2026-03-24 | 999.24 |
| 2026-01-21 | 2026-02-16 | 0.34 |
| 2025-11-18 | 2025-11-24 | 161.65 |
| 2023-07-18 | 2023-07-18 | 701.76 |
| 2023-03-16 | 2023-03-22 | 111.00 |
| 2023-02-17 | 2023-02-23 | 112.14 |
| 2022-07-18 | 2022-07-19 | 674.53 |
| 2021-12-30 | 2022-01-13 | 0.06 |
| 2021-12-16 | 2021-12-29 | 0.01 |
| 2021-11-16 | 2021-12-13 | 1.09 |
| 2021-09-28 | 2021-10-10 | 2.11 |
Fama Bona klinika - VMI tax arrears
The company had no tax arrears (debts) to the State Tax Inspectorate
VMI debt information has been collected since 2024-10-07. Debts for older periods will not be displayed.
Analysis of the company's financial position
This description was generated by artificial intelligence.
Report if inaccurate.
Fama Bona, UAB (code 300648651) is a Private Limited Liability Company engaged in medical specialists activities. In 2025, the company generated revenue of €76.6K, up 7.6% year on year and 5.5% above the 2023 level. Net profit amounted to €11.4K, following €17.4K in 2024 and €27.0K in 2023, showing a clear decline in earnings over the three-year period despite the rebound in sales. The profit margin decreased to 14.8% in 2025 from 24.5% in 2024 and 37.2% in 2023. The balance sheet strengthened in size, with total assets rising to €144.0K, while equity turned positive at €2.6K after negative equity in the previous two years. Liabilities were €141.4K, indicating a highly leveraged structure. Asset turnover was 0.53x, and revenue per employee was €4.0K, with profit per employee at €598. The latest year therefore shows moderate top-line growth, weaker profitability, and a still thin equity base.